Cell Medica, a leader in developing, marketing and manufacturing cellular therapeutics for cancer and infections, announced a ground-breaking co-development partnership with Baylor College of Medicine (Baylor).
The collaboration provides Cell Medica with an exclusive license over several Baylor cell and gene technologies and an option to license new products introduced into the co-development partnership by Baylor’s leading research teams in the field of genetically engineered immune cells.
The partnership will seek to develop next-generation technologies for engineering immune cells with enhanced functions for the treatment of solid tumors.
Baylor will be responsible for pre-clinical through Phase I clinical research.
Cell Medica will leverage its substantial experience in manufacturing clinical-grade cell therapies to establish efficient and effective production processes suitable for industrial scale-up.
Financial advisor to Baylor College of Medicine.